These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33965574)

  • 1. Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation.
    Tack J; Camilleri M; Hale M; Morlion B; Nalamachu S; Webster L; Wild J
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):855-863. PubMed ID: 33965574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies.
    Camilleri M; Hale M; Morlion B; Tack J; Webster L; Wild J
    J Pain Res; 2021; 14():2179-2189. PubMed ID: 34295186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    Ann Oncol; 2018 Jun; 29(6):1461-1467. PubMed ID: 32151367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.
    Saito Y; Yokota T; Arai M; Tada Y; Sumitani M
    J Pain Res; 2019; 12():127-138. PubMed ID: 30613161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
    Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
    Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.
    Marciniak CM; Toledo S; Lee J; Jesselson M; Bateman J; Grover B; Tierny J
    World J Gastroenterol; 2014 Nov; 20(43):16323-33. PubMed ID: 25473191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Webster LR; Yamada T; Arjona Ferreira JC
    Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating Clinical Findings into the Patient's Perspective: Post-hoc Pooled Analysis of Bowel Movement Changes as a Predictor of Improvement in Patients' Opioid-induced Constipation Symptoms and Outcomes.
    Coyne KS; Poon JL; Thompson C; Hu Y; Datto CJ; Sostek M
    Clin Ther; 2017 Jan; 39(1):75-88. PubMed ID: 27938897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer.
    Fumita S; Imai H; Harada T; Noriyuki T; Gamoh M; Akashi Y; Sato H; Kizawa Y; Tokoro A
    J Pain Symptom Manage; 2020 May; 59(5):1043-1051.e2. PubMed ID: 31805362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
    Liu JJ; Quinton SE; Brenner DM
    Pain Manag; 2020 Sep; 10(5):301-306. PubMed ID: 32552565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride.
    Tack J; Camilleri M; Dubois D; Vandeplassche L; Joseph A; Kerstens R
    Neurogastroenterol Motil; 2015 Mar; 27(3):397-405. PubMed ID: 25581251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference.
    Yiannakou Y; Tack J; Piessevaux H; Dubois D; Quigley EMM; Ke MY; Da Silva S; Joseph A; Kerstens R
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1103-1111. PubMed ID: 28983926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study.
    Cobo Dols M; Beato Zambrano C; Cabezón-Gutiérrez L; Chicas-Sett R; Blancas López-Barajas MI; García Navalón FJ; Fírvida Pérez JL; Serrano Bermúdez G; Togores Torres P; Delgado Mingorance I; Giraldo Marín A; Librán Oriol A; Paredes Lario A; Sánchez Mauriño P; Higuera Gómez O; Moreno Muñoz D; Huerta González I; Sanz-Yagüe A; Soler López B
    BMJ Support Palliat Care; 2023 Dec; 13(e2):e318-e326. PubMed ID: 33707299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
    Slappendel R; Simpson K; Dubois D; Keininger DL
    Eur J Pain; 2006 Apr; 10(3):209-17. PubMed ID: 15914049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.
    Sloots CE; Rykx A; Cools M; Kerstens R; De Pauw M
    Dig Dis Sci; 2010 Oct; 55(10):2912-21. PubMed ID: 20428949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation.
    Argoff CE; Brennan MJ; Camilleri M; Davies A; Fudin J; Galluzzi KE; Gudin J; Lembo A; Stanos SP; Webster LR
    Pain Med; 2015 Dec; 16(12):2324-37. PubMed ID: 26582720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naldemedine: A Review in Opioid-Induced Constipation.
    Blair HA
    Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.